SG158096A1 - Dosage regimen of an s1p receptor agonist - Google Patents

Dosage regimen of an s1p receptor agonist

Info

Publication number
SG158096A1
SG158096A1 SG200907947-6A SG2009079476A SG158096A1 SG 158096 A1 SG158096 A1 SG 158096A1 SG 2009079476 A SG2009079476 A SG 2009079476A SG 158096 A1 SG158096 A1 SG 158096A1
Authority
SG
Singapore
Prior art keywords
daily dosage
receptor agonist
dosage regimen
dosage
standard
Prior art date
Application number
SG200907947-6A
Other languages
English (en)
Inventor
John M Kovarik
Silke Appel-Dingemanse
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG158096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG158096A1 publication Critical patent/SG158096A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
SG200907947-6A 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist SG158096A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29

Publications (1)

Publication Number Publication Date
SG158096A1 true SG158096A1 (en) 2010-01-29

Family

ID=36046868

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200907947-6A SG158096A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist
SG2013002662A SG187468A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013002662A SG187468A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Country Status (22)

Country Link
US (3) US20090275553A1 (sh)
EP (3) EP1819326B1 (sh)
JP (4) JP2008521827A (sh)
KR (4) KR20150028858A (sh)
CN (2) CN101068536B (sh)
AU (1) AU2005309378B2 (sh)
BR (1) BRPI0518674A2 (sh)
CA (1) CA2589265A1 (sh)
ES (1) ES2495690T3 (sh)
HK (1) HK1109057A1 (sh)
IL (2) IL183134A0 (sh)
MA (1) MA29034B1 (sh)
MX (1) MX2007006373A (sh)
NO (2) NO20072401L (sh)
NZ (2) NZ590054A (sh)
PL (1) PL1819326T3 (sh)
PT (1) PT1819326E (sh)
RU (2) RU2478384C2 (sh)
SG (2) SG158096A1 (sh)
TN (1) TNSN07209A1 (sh)
WO (1) WO2006058316A1 (sh)
ZA (1) ZA200703328B (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
RU2478384C2 (ru) * 2004-11-29 2013-04-10 Новартис Аг Курс лечения с использованием агониста рецептора s1p
EP1926483B1 (en) * 2005-09-09 2010-12-01 Novartis AG Treatment of autoimmune diseases
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CN104337808A (zh) 2007-05-04 2015-02-11 诺华股份有限公司 S1p受体调节剂的用途
SI2278960T2 (sl) 2008-03-17 2020-02-28 Actelion Pharmaceuticals Ltd. Režim odmerjanja za selektivni agonist receptorja sip1
US20110152275A1 (en) * 2008-05-20 2011-06-23 Kazuhiko Kuriyama Agent for maintenance of induced remission
JP5878015B2 (ja) * 2008-07-23 2016-03-08 ノバルティス アーゲー スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用
CN102186473B (zh) * 2008-08-18 2014-07-02 诺华股份有限公司 用于治疗周围神经病的化合物
SG171785A1 (en) * 2008-12-18 2011-07-28 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
BRPI0922466A2 (pt) * 2008-12-18 2018-10-23 Novartis Ag sais
AU2009327405A1 (en) * 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
EA201100978A1 (ru) * 2008-12-22 2012-01-30 Новартис Аг Схема приема агониста рецептора s1p
RU2561681C2 (ru) * 2008-12-22 2015-08-27 Новартис Аг Схема приема агониста рецептора s1p
AU2010101513B4 (en) 2009-09-29 2016-05-05 Novartis Ag Dosage regimen of an S1P receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
WO2011138398A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
WO2013057212A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
CA2895172C (en) 2012-08-17 2020-08-18 Actelion Pharmaceuticals Ltd Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
MY188764A (en) 2014-12-11 2021-12-30 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
IL292529A (en) 2019-10-31 2022-06-01 Idorsia Pharmaceuticals Ltd Combination of cxcr7 antagonist with s1p1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
ES2171191T3 (es) 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
AU705320B2 (en) * 1995-12-28 1999-05-20 Welfide Corporation 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
AU735406B2 (en) * 1997-02-27 2001-07-05 Novartis Ag Pharmaceutical composition
DE69825056T2 (de) 1997-04-04 2005-08-25 Mitsubishi Pharma Corp. 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
PL359411A1 (en) 2000-07-13 2004-08-23 Sankyo Company, Limited Amino alcohol derivatives
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
PL367348A1 (en) 2001-03-26 2005-02-21 Novartis Ag 2-amino-propanol derivatives
IL157955A0 (en) * 2001-04-02 2004-03-28 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
IL157946A0 (en) * 2001-04-02 2004-03-28 Genentech Inc Combination therapy
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ATE424893T1 (de) * 2001-06-08 2009-03-15 Novartis Pharma Gmbh Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
DK1431284T3 (da) 2001-09-27 2008-02-18 Kyorin Seiyaku Kk Diarylsulfidderivat, additionssalt deraf samt immunundertrykkende middel
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
AU2003216054B2 (en) * 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
JP4430941B2 (ja) * 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
CN1708293A (zh) * 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
TW200505442A (en) 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
RU2478384C2 (ru) * 2004-11-29 2013-04-10 Новартис Аг Курс лечения с использованием агониста рецептора s1p
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Also Published As

Publication number Publication date
BRPI0518674A2 (pt) 2008-12-02
KR20140095109A (ko) 2014-07-31
KR20070085465A (ko) 2007-08-27
JP2008521827A (ja) 2008-06-26
WO2006058316A1 (en) 2006-06-01
MX2007006373A (es) 2007-06-20
SG187468A1 (en) 2013-02-28
PT1819326E (pt) 2014-09-25
EP2359821A1 (en) 2011-08-24
TNSN07209A1 (en) 2008-11-21
ZA200703328B (en) 2008-08-27
JP2013129664A (ja) 2013-07-04
US20120071446A1 (en) 2012-03-22
NO20072401L (no) 2007-06-22
JP2015061883A (ja) 2015-04-02
ES2495690T3 (es) 2014-09-17
HK1109057A1 (en) 2008-05-30
PL1819326T3 (pl) 2014-12-31
RU2012141951A (ru) 2014-04-10
IL223502A0 (en) 2013-02-03
CN101068536A (zh) 2007-11-07
JP2012107059A (ja) 2012-06-07
AU2005309378B2 (en) 2010-02-11
AU2005309378A1 (en) 2006-06-01
RU2478384C2 (ru) 2013-04-10
EP1819326A1 (en) 2007-08-22
MA29034B1 (fr) 2007-11-01
CN102600472A (zh) 2012-07-25
CN101068536B (zh) 2012-12-05
EP2384749A1 (en) 2011-11-09
CA2589265A1 (en) 2006-06-01
EP1819326B1 (en) 2014-07-02
NZ590054A (en) 2012-07-27
IL183134A0 (en) 2008-04-13
US20150087720A1 (en) 2015-03-26
KR20130041385A (ko) 2013-04-24
RU2007124327A (ru) 2009-01-10
NO20121305L (no) 2007-06-22
KR20150028858A (ko) 2015-03-16
US20090275553A1 (en) 2009-11-05
NZ554720A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
SG158096A1 (en) Dosage regimen of an s1p receptor agonist
MX2011006625A (es) Regimen de dosificacion de un agonista de los receptores de s1p.
MX2021010759A (es) Regimen de dosificacion para un agonista de los receptores de s1p.
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MXPA02007690A (es) Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide.
EP2335734A3 (en) Treatment of pain and other alpha 2 adrenergic-mediated conditions
MX2007000009A (es) Forma farmaceutica oral, protegida frente al abuso.
AU2003275357A1 (en) Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride
EP2044940A3 (en) Methods of treating patients suffering from movement disorders
MX2007005570A (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
EP1461015A4 (en) COMPOSITIONS CONTAINING SEDATIVE ANTIHISTAMINES AND NON-SEDATIVE ANTIHISTAMINES
WO2006000567A3 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
IL194885A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid
TNSN05256A1 (en) Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol
EA200501817A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
MXPA06002726A (es) Metodo para identificar agonistas mejorados no sedantes de alfa-2.
IL178591A (en) 4– (Amino) –2– (2,6 – Dioxo (3-piperidyl)) - Isoindulin – 1,3 – Dion for the treatment and management of myelodysplastic syndromes
HK1127289A1 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl- propyl) -phenol and paracetamol
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
HK1127556A1 (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases